P2X Receptors As Targets for the Treatment of Status Epilepticus

Overview

Journal Front Cell Neurosci

Specialty Cell Biology

Date 2013 Dec 11

PMID 24324404

Citations 20

Authors

David C Henshall

Miguel Diaz-Hernandez

M Teresa Miras-Portugal

Tobias Engel

Affiliations

Soon will be listed here.

Abstract

Prolonged seizures are amongst the most common neurological emergencies. Status epilepticus is a state of continuous seizures that is life-threatening and prompt termination of status epilepticus is critical to protect the brain from permanent damage. Frontline treatment comprises parenteral administration of anticonvulsants such as lorazepam that facilitate γ-amino butyric acid (GABA) transmission. Because status epilepticus can become refractory to anticonvulsants in a significant proportion of patients, drugs which act on different neurotransmitter systems may represent potential adjunctive treatments. P2X receptors are a class of ligand-gated ion channel activated by ATP that contributes to neuro- and glio-transmission. P2X receptors are expressed by both neurons and glia in various brain regions, including the hippocampus. Electrophysiology, pharmacology and genetic studies suggest certain P2X receptors are activated during pathologic brain activity. Expression of several members of the family including P2X2, P2X4, and P2X7 receptors has been reported to be altered in the hippocampus following status epilepticus. Recent studies have shown that ligands of the P2X7 receptor can have potent effects on seizure severity during status epilepticus and mice lacking this receptor display altered seizures in response to chemoconvulsants. Antagonists of the P2X7 receptor also modulate neuronal death, microglial responses and neuroinflammatory signaling. Recent work also found altered neuronal injury and inflammation after status epilepticus in mice lacking the P2X4 receptor. In summary, members of the P2X receptor family may serve important roles in the pathophysiology of status epilepticus and represent novel targets for seizure control and neuroprotection.

Citing Articles

Proteomic analysis discovers potential biomarkers of early traumatic axonal injury in the brainstem.

Chen Q, Li L, Xu L, Yang B, Huang Y, Qiao D Int J Legal Med. 2023; 138(1):207-227.

PMID: 37338605 DOI: 10.1007/s00414-023-03039-5.

Pyridoxine-responsive KCNQ2 epileptic encephalopathy: Additional cases and literature review.

Chen J, Tao Q, Fan L, Shen Y, Liu J, Luo H Mol Genet Genomic Med. 2022; 10(10):e2024.

PMID: 35906921 PMC: 9544210. DOI: 10.1002/mgg3.2024.

Amore G, Butera A, Spoto G, Valentini G, Saia M, Salpietro V Front Neurol. 2022; 13:826225.

PMID: 35401395 PMC: 8992372. DOI: 10.3389/fneur.2022.826225.

P2X Receptors in Neurodegeneration: Potential Therapeutic Applications From Basic to Clinical Approaches.

Territo P, Zarrinmayeh H Front Cell Neurosci. 2021; 15:617036.

PMID: 33889073 PMC: 8055960. DOI: 10.3389/fncel.2021.617036.

The Role of NMDA Receptors in the Effect of Purinergic P2X7 Receptor on Spontaneous Seizure Activity in WAG/Rij Rats With Genetic Absence Epilepsy.

Doan E, Aygun H, Arslan G, Rzayev E, Avci B, Ayyildiz M Front Neurosci. 2020; 14:414.

PMID: 32435183 PMC: 7218146. DOI: 10.3389/fnins.2020.00414.

References

Sperlagh B, Heinrich A, Csolle C . P2 receptor-mediated modulation of neurotransmitter release-an update. Purinergic Signal. 2008; 3(4):269-84. PMC: 2072919. DOI: 10.1007/s11302-007-9080-0. View

Marchi N, Fan Q, Ghosh C, Fazio V, Bertolini F, Betto G . Antagonism of peripheral inflammation reduces the severity of status epilepticus. Neurobiol Dis. 2008; 33(2):171-81. PMC: 3045783. DOI: 10.1016/j.nbd.2008.10.002. View

SOLLE M, Labasi J, Perregaux D, Stam E, Petrushova N, Koller B . Altered cytokine production in mice lacking P2X(7) receptors. J Biol Chem. 2000; 276(1):125-32. DOI: 10.1074/jbc.M006781200. View

Khakh B, Gittermann D, Cockayne D, Jones A . ATP modulation of excitatory synapses onto interneurons. J Neurosci. 2003; 23(19):7426-37. PMC: 6740451. View

Seguela P, Haghighi A, Soghomonian J, Cooper E . A novel neuronal P2x ATP receptor ion channel with widespread distribution in the brain. J Neurosci. 1996; 16(2):448-55. PMC: 6578647. View

Kim M, Jiang L, Wilson H, North R, Surprenant A . Proteomic and functional evidence for a P2X7 receptor signalling complex. EMBO J. 2001; 20(22):6347-58. PMC: 125721. DOI: 10.1093/emboj/20.22.6347. View

Engel T, Gomez-Villafuertes R, Tanaka K, Mesuret G, Sanz-Rodriguez A, Garcia-Huerta P . Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice. FASEB J. 2011; 26(4):1616-28. DOI: 10.1096/fj.11-196089. View

Lopatar J, Dale N, Frenguelli B . Minor contribution of ATP P2 receptors to electrically-evoked electrographic seizure activity in hippocampal slices: Evidence from purine biosensors and P2 receptor agonists and antagonists. Neuropharmacology. 2011; 61(1-2):25-34. DOI: 10.1016/j.neuropharm.2011.02.011. View

Nicke A, Kuan Y, Masin M, Rettinger J, Marquez-Klaka B, Bender O . A functional P2X7 splice variant with an alternative transmembrane domain 1 escapes gene inactivation in P2X7 knock-out mice. J Biol Chem. 2009; 284(38):25813-22. PMC: 2757983. DOI: 10.1074/jbc.M109.033134. View

10.

Devinsky O, Vezzani A, Najjar S, de Lanerolle N, Rogawski M . Glia and epilepsy: excitability and inflammation. Trends Neurosci. 2013; 36(3):174-84. DOI: 10.1016/j.tins.2012.11.008. View

11.

Bhattacharya A, Wang Q, Ao H, Shoblock J, Lord B, Aluisio L . Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br J Pharmacol. 2013; 170(3):624-40. PMC: 3792000. DOI: 10.1111/bph.12314. View

12.

Armstrong J, Brust T, Lewis R, MacVicar B . Activation of presynaptic P2X7-like receptors depresses mossy fiber-CA3 synaptic transmission through p38 mitogen-activated protein kinase. J Neurosci. 2002; 22(14):5938-45. PMC: 6757920. DOI: 20026618. View

13.

Deuchars S, Atkinson L, Brooke R, Musa H, Milligan C, Batten T . Neuronal P2X7 receptors are targeted to presynaptic terminals in the central and peripheral nervous systems. J Neurosci. 2001; 21(18):7143-52. PMC: 6762981. View

14.

Boison D . The adenosine kinase hypothesis of epileptogenesis. Prog Neurobiol. 2008; 84(3):249-62. PMC: 2278041. DOI: 10.1016/j.pneurobio.2007.12.002. View

15.

Iglesias R, Locovei S, Roque A, Alberto A, Dahl G, Spray D . P2X7 receptor-Pannexin1 complex: pharmacology and signaling. Am J Physiol Cell Physiol. 2008; 295(3):C752-60. PMC: 2544446. DOI: 10.1152/ajpcell.00228.2008. View

16.

Bernardino L, Balosso S, Ravizza T, Marchi N, Ku G, Randle J . Inflammatory events in hippocampal slice cultures prime neuronal susceptibility to excitotoxic injury: a crucial role of P2X7 receptor-mediated IL-1beta release. J Neurochem. 2008; 106(1):271-80. DOI: 10.1111/j.1471-4159.2008.05387.x. View

17.

Cavaliere F, Amadio S, Dinkel K, Reymann K, Volonte C . P2 receptor antagonist trinitrophenyl-adenosine-triphosphate protects hippocampus from oxygen and glucose deprivation cell death. J Pharmacol Exp Ther. 2007; 323(1):70-7. DOI: 10.1124/jpet.106.119024. View

18.

Yu Q, Guo Z, Liu X, Ouyang Q, He C, Burnstock G . Block of P2X7 receptors could partly reverse the delayed neuronal death in area CA1 of the hippocampus after transient global cerebral ischemia. Purinergic Signal. 2013; 9(4):663-75. PMC: 3889395. DOI: 10.1007/s11302-013-9379-y. View

19.

Matute C, Torre I, Perez-Cerda F, Perez-Samartin A, Alberdi E, Etxebarria E . P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J Neurosci. 2007; 27(35):9525-33. PMC: 6673129. DOI: 10.1523/JNEUROSCI.0579-07.2007. View

20.

Curia G, Longo D, Biagini G, Jones R, Avoli M . The pilocarpine model of temporal lobe epilepsy. J Neurosci Methods. 2008; 172(2):143-57. PMC: 2518220. DOI: 10.1016/j.jneumeth.2008.04.019. View